StockNews.com initiated coverage on shares of Curis (NASDAQ:CRIS – Free Report) in a research report report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.
Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Curis in a report on Tuesday, December 10th.
Read Our Latest Report on CRIS
Curis Stock Performance
Institutional Trading of Curis
Several institutional investors and hedge funds have recently made changes to their positions in CRIS. Squarepoint Ops LLC bought a new stake in shares of Curis in the fourth quarter valued at about $35,000. Millennium Management LLC raised its holdings in shares of Curis by 92.6% in the fourth quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 12,287 shares in the last quarter. Focused Wealth Management Inc raised its holdings in shares of Curis by 9.5% in the fourth quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock valued at $181,000 after acquiring an additional 5,138 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Curis by 27.3% in the fourth quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock valued at $254,000 after acquiring an additional 17,820 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Curis in the fourth quarter valued at about $607,000. 29.97% of the stock is currently owned by institutional investors.
About Curis
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Featured Stories
- Five stocks we like better than Curis
- Using the MarketBeat Dividend Yield Calculator
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- The Basics of Support and Resistance
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Industrial Products Stocks Investing
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.